The ViroKey SQ FLEX SARS-CoV-2 Genotyping Assay harnesses next-generation sequencing technology to sequence the whole SARS-CoV-2 genome.
The accompanying Sentosa SQ Reporter software calls out mutations and classifies them by lineage, thereby aiding in the research and understanding of the molecular epidemiology of the COVID-19 pandemic.
According to WHO, whole genome sequencing is essential for improving effectiveness/sensitivity of molecular diagnostics, serological assays, vaccine design and anti-viral therapy, and aiding investigation of transmission routes and outbreak clusters.
The ViroKey SARS-CoV-2 ID RT-PCR Test is able to quickly identify variants present in positive samples. Variants include the B.1.1.7, B.1.351 (South Africa) and P.1 (Brazil) lineages.
The variant identification test can be used in conjunction with the ViroKey SARS-CoV-2 RT-PCR Test v2.0, which has received FDA Emergency Use Authorization, CE-IVD and TGA approval, and HSA Provisional Authorization.
Vela Diagnostics is a provider for integrated IVD system solutions.
Vela's test solutions utilize the automated Sentosa platform, providing the ability to leverage one system for NGS and PCR testing in infectious disease and oncology.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT